

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER Medical Holdings Limited

希瑪醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

The board of directors (the “**Board**”) of C-MER Medical Holdings Limited (the “**Company**”, together with its subsidiaries (the “**Group**”)) is pleased to announce that on 29 September 2025, a subsidiary of Health Hope Pharma Limited (“**HHP**”), has entered into a tri-partite global licensing and collaboration agreement with Gilead Sciences, Inc. (“**Gilead**”) and Hanmi Pharm. Co., LTD. (“**Hanmi**”), for encequidar, a first-in-class P-glycoprotein (“**P-gp**”) inhibitor in the field of virology, of which HHP holds the global exclusive rights over (other than Korea).

Under the agreement, HHP and Hanmi will grant Gilead the exclusive global rights to encequidar within the field of virology. In addition, HHP and Hanmi will provide drug supply, share technical know-how, and participate as key project partners. Subject to the fulfillment of certain conditions and milestones during the terms of the agreement, HHP will receive an upfront payment of US\$10 million and may be eligible to receive potential future payments of up to approximately US\$72.5 million and low single-digit royalties on net sales.

HHP is primarily involved in the development of innovative drug projects in the field of oncology, and it is currently exploring the potential of using encequidar to develop oral drug formulations across multiple fields. The most advanced program of HHP is oral paclitaxel combined with encequidar in the field of oncology for metastatic breast cancer, targeting to replace intravenous paclitaxel in chemotherapy. HHP is preparing for the commencement of phase 3 global multicenter clinical trial of oral paclitaxel combined with encequidar for metastatic breast cancer in the U.S., Hong Kong, and New Zealand by 2025.

INFORMATION ABOUT HHP

To align with our strategy to invest in the upstream business opportunities in the value chain and create growth momentum for the Group, and leveraging on Dr. Dennis LAM's (our founder and one of our controlling shareholders) medical expertise, global network and reputation to have good access to innovative drug projects in the fields of ophthalmology and oncology, the Group and Dr. Dennis LAM established HHP as a joint venture company in July 2023. Subsequently, HHP acquired a portfolio of oral anti-cancer drug programs and all the relevant patents from Athenex, Inc., through an auction in the U.S. HHP is now a clinical-stage biotech company with operations in Hong Kong, the U.S. and UK.

As of the date of this announcement, HHP is held as to 21.8% by the Group and is an associated company that is accounted for as a financial asset at fair value through other comprehensive income of our Group, and HHP is majority controlled by Dr. Dennis LAM.

This announcement is made on a voluntary basis by the Company to inform the public of the latest status on the business development of HHP.

By order of the Board
C-MER Medical Holdings Limited
Ms. LI Xiaoting

Vice Chairman, Executive Director and Chief Executive Officer

Hong Kong, 29 September 2025

As at the date of this announcement, the Board comprises its chairman and independent non-executive Director, Dr. Rex AU YEUNG Pak-ken; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.